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Abstract
Background: Globally cryptosporidiosis is one of the commonest causes of mortality in children under 24 months
old and may be associated with important longterm health effects. Whilst most strains of Cryptosporidium parvum
are zoonotic, C. parvum IIc is almost certainly anthroponotic. The global distribution of this potentially important
emerging infection is not clear.
Methods: We conducted a systematic review of papers identifying the subtype distribution of C. parvum infections
globally. We searched PubMed and Scopus using the following key terms Cryptospor* AND parvum AND (genotyp*
OR subtyp* OR gp60). Studies were eligible for inclusion if they had found C. parvum within their human study
population and had subtyped some or all of these samples using standard gp60 subtyping. Pooled analyses of the
proportion of strains being of the IIc subtype were determined using StatsDirect. Meta-regression analyses were run
to determine any association between the relative prevalence of IIc and Gross Domestic Product, proportion of the
population with access to improved drinking water and improved sanitation.
Results: From an initial 843 studies, 85 were included in further analysis. Cryptosporidium parvum IIc was found in 43 of
these 85 studies. Across all studies the pooled estimate of relative prevalence of IIc was 19.0% (95% CI: 12.9–25.9%), but
there was substantial heterogeneity. In a meta-regression analysis, the relative proportion of all C. parvum infections
being IIc decreased as the percentage of the population with access to improved sanitation increased and was some
3.4 times higher in those studies focussing on HIV-positive indivduals.
Conclusions: The anthroponotic C. parvum IIc predominates primarily in lower-income countries with poor sanitation
and in HIV-positive individuals. Given the apparent enhanced post-infectious virulence of the other main anthroponotic
species of Cryptosporidium (C. hominis), it is important to learn about the impact of this subtype on human health.
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Background
Cryptosporidium spp. are enteric protozoan parasites
found globally throughout the world. They are ubiqui-
tous in the environment and capable of causing infection
in both immunocompetent and immunocompromised
humans as well as a wide variety of animals. Their ability
to cause both sporadic episodes of disease as well as more
far-reaching food and waterborne outbreaks is becoming
increasingly recognised [1, 2]
Cryptosporidium spp. are now one of the major causes
of mortality from an infectious disease in children under
24 months in low income countries and are associated with
an increased risk of death in toddlers aged 12–23 months
[3]. Even in children who survive, there is growing evidence
of a link between cryptosporidiosis, childhood malnutrition
and stunting in such countries [4]. It has been estimated
that in 2015 1.3 million deaths worldwide were due to
diarrhoeal disease, and Cryptosporidium spp. are the
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second commonest cause of death from diarrhoeal disease
in children under five years, after Rotavirus [5]. However,
whilst Rotavirus has an internationally available vaccine
that is successfully reducing numbers of severe gastro-in-
testinal disease and death [6], Cryptosporidium spp. have
neither a vaccine nor effective treatment to reduce its
morbidity and mortality.
Although there have been reported cases of human
infection from at least 17 species of Cryptosporidium, C.
hominis and C. parvum are the two species that have
been most associated with causing human disease [7].
Subtyping of Cryptosporidium species, specifically C.
hominis and C. parvum, can provide clarity of mode of
transmission in addition to being important epidemiological
tools, especially in outbreak situations. At present, the most
commonly used and accepted method of subtyping is
through sequencing of the gp60 gene, a 60-kDa glycopro-
tein. The gp60 gene has a number of tandem repeats at the
5' end of the gene consisting of TCA, TCG or TCT [8] and
also further variation in the non-repeat 3' end of the gene,
enabling classification of C. hominis and C. parvum into
subtype families on the basis of the number and type of
trinucleotide repeat [9].
Cryptosporidium parvum IIc is of particular interest
as it appears to be anthroponotic, i.e. host- restricted to
humans, which is in direct contrast to most other sub-
type families of C. parvum, which cause disease in both
humans and animals [8].
Cryptosporidium genotypes and isolates vary in their
virulence, with over 25 putative virulence factors identi-
fied [10]. Hunter et al. [11] showed that C. hominis was
associated with an increased risk of post-infectious sequelae
compared with C. parvum [11] and Cama et al. [12]
suggested C. hominis Ib is more pathogenic than other
subtypes. However, the differences in virulence of C.
parvum subtypes have not been systemically studied,
and there are very little data available linking subtype to
pathology. As existing evidence suggests anthroponotic
Cryptosporidium spp. are more virulent than zoonotic
Cryptosporidium spp, then as C. parvum IIc is transmitted
anthroponotically like C. hominis, it may display enhanced
virulence like C. hominis.
The worldwide distribution of C. parvum IIc has not
been systematically studied or documented. Thus we
aimed to identify all studies that had subtyped C. par-
vum using gp60 subtyping methods, to characterise
the endemic worldwide distribution and proportion of
C. parvum IIc and investigate how this differs
throughout the world, in particular exploring potential
links with gross domestic product (GDP), a measure
of economic growth and often used as a proxy for
standard of living, and sanitation, in order to provide
clarity on proportion and distribution of anthroponotic C.
parvum IIc.
Methods
Search strategy
PubMed and Scopus were searched up to and including
1st November 2016 using the following search strategy:
Cryptospor* AND parvum AND (genotyp* OR subtyp*
OR gp60) without restriction on language or study type.
Review articles and book chapters were additionally
reviewed for references which would fit the inclusion
criteria.
Eligibility criteria
Studies were eligible for inclusion if they had found C.
parvum within their study population and had subtyped
some or all of these samples using the standard gp60
subtyping classification. The study population of interest
was restricted to humans, thus studies which had subtyped
C. parvum found in animals were excluded, but for studies
that had included both animals and humans the subtyping
data for humans only was included. Reviews and editorials
were excluded. Studies which reported subtyping of
outbreaks were excluded as the aim was to identify the
endemic worldwide proportion of C. parvum IIc.
If studies had included data from a previous study,
only one study was included to prevent duplication of
data.
Data including country of study, population character-
istics, subtypes found, number of samples of subtypes
found and total number of C. parvum samples subtyped
were extracted onto a datasheet by one of the researchers.
Independently a second researcher reviewed the studies
included in the search and their inclusion or exclusion in
the final dataset.
Eligible studies were screened initially by title and abstract,
and included if they met the inclusion criteria and full text
retrieved. If it was unclear from the title and abstract
whether the inclusion criteria were met, then the full paper
was reviewed and decision made regarding inclusion or
exclusion.
Statistical analysis
Proportion of C. parvum IIc in relation to total C. par-
vum was calculated using the number of samples of C.
parvum IIc and the total C. parvum samples subtyped
using gp60 subtyping classification. Forest plots and pooled
prevalence estimations were performed using STATS
Direct™. When investigating drivers of heterogeneity,
negative binomial regression analyses were carried out
using STATA™. Given the known association of crypto-
sporidiosis with drinking water associated outbreaks,
the faecal oral transmission pathway and the anthropo-
notic nature of C. parvum IIc, we hypothesised that
much of the heterogeneity between countries could be
explained by variation in access to improved drinking
water and sanitation. In constructing the regression
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analyses we took data on Gross Domestic capita per
person, % of the population with access to improved
sanitation and % of the population with access to an
improved water supply. All three variables were taken
from the World Bank World Development Indicators
Archive [13] and for the year when the study was
undertaken or published. Gross domestic product per
capita (GDPpc) was expressed in USD for year 2005.
The definitions of improved sanitation and improved
water supply were as used by the World Bank which
are themselves taken from the definitions of the WHO/
UNICEF Joint Monitoring Programme [14]. All three
country-specific variables were taken to be two years
prior to the publication date to adjust for time of collection
to publication. Given the marked skewedness of the GDP
data we used the log10-transformed data. In addition,
publication year and whether or not a focus of the
study was Cryptosporidium infections in HIV-positive
individuals were also included in the analysis. The regres-
sion analysis was run with all predictors individually and
then all in a single model removing the least statistically
significant until all variables were significant at the P < 0.2
level.
PRISMA guidelines were followed in the preparation
of this manuscript (see PRISMA checklist in Additional
file 1: Table S1).
Results
The PubMed search gave a total of 750 results, and the
Scopus search revealed an additional 90 unique studies.
Reviewing of references in review articles and book
chapters identified three further studies with subtyping
information on C. parvum, resulting in a total of 843
unique studies.
A total of 732 studies were excluded for failing to meet
the inclusion criteria, mainly because they were not original
studies with subtyping information or had only included
animals or environmental samples. A further 23 studies
were excluded as they were studies of outbreaks, as the aim
was to characterise the endemic proportion of C. parvum
IIc. Two further studies were excluded as they contained
duplication of material presented in other already included
studies. The final number of studies included was 85 (Fig. 1,
Table 1).
Study characteristics
Of the 85 studies included, many (n = 28) were solely in
children, 23 studies included both children and adults,
and 14 studies focused on HIV positive or AIDS patients.
Some studies did not specify the human population they
were studying.
Studies had taken place in a wide variety of countries,
including high- and low-income countries and both rural
and urban settings.
The number of samples subtyped in most studies was
small, ranging from 1 to 249 samples. Included studies
were published between 2001 and 2016, with the majority
of studies published in the later years, reflecting increased
access to molecular techniques.
Cryptosporidium parvum IIc distribution
Cryptosporidium parvum IIc was found in 43 studies. In
10 studies, C. parvum IIc was the only subtype of C.
parvum to be found. Across all studies the proportion of
C. parvum strains typed as IIc using a random effects
meta-analysis is 19.0% (95% CI, 12.9–25.9%). However,
there was evidence of substantial heterogeneity [Cochran
Q = 964.365229, df = 84, P < 0.0001; I2 (inconsistency) =
91.3% (95% CI: 90.1–92.3%)]. The estimates of the pooled
proportions for all the GP60 subtypes are shown in
Table 2, and Additional file 2: Figure S1 gives the forest
plots for the three most common subtypes. It can be seen
from Table 2 that the great majority of strains are either
IIa, IIc or IId which together account for about 84% of
human infections. The remaining 9 subtypes are only
detected very rarely, with IIe representing an estimated
2.7% of infections.
Even from a simple visual inspection of the data, it
was clear that C. parvum IIc was particularly common
in middle- and low-income countries.
Mbae et al. [15] investigated the distribution of
Cryptosporidium and diversity of subtypes in children
in urban Kenya. Of the 19 samples of C. parvum they
subtyped, all were the anthroponotic IIc subtype, with
no other reported subtypes found. This predominant
finding of high numbers of C. parvum IIc was also
found in children in rural Ghana, with 81% of the sub-
typed C. parvum samples found to be the IIc subtype
[16]. This finding was also replicated in HIV-positive
patients in Equatorial Guinea [17], children in Nigeria
[18], HIV-positive patients in Jamaica [19], both HIV-
positive patients and children in Peru [12, 20] and children
in both India and Uganda [21, 22].
In contrast, high income countries reported much lower
numbers of C. parvum IIc as a proportion of total C. par-
vum subtyped. Often European studies did not find C.
parvum IIc amongst their samples, or if they did it tended
to be at low levels. Insulander et al. [23] studied adults
and children in Sweden and found a C. parvum IIc pro-
portion of just 11%. This finding was replicated by
Chalmers et al. [24] studying adults and children in
England and Wales who found C. parvum IIc in 2% of
their C. parvum-subtyped samples, and Wielinga et al.
[25] who reported a C. parvum IIc proportion of 8%
from humans in the Netherlands. Studies in Australia
and New Zealand tended to report either a very low
proportion of C. parvum IIc, e.g. Waldron et al. [26]
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Fig. 1 Flow chart depicting inclusion and exclusion of studies with numbers
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Table 1 Cryptosporidium parvum subtype frequency distributions in published literature ranked by continent and country.
Reference Country Population Total number C. parvum isolates
subtyped and numbers of subtypes
Proportion C. parvum IIc
of C. parvum subtyped (%)
Asia
[48] Bangladesh Children (n = 4) (4 × IIm) 0
[49] Cambodia Children (n = 4) (4 × IIe ) 0
[50] China HIV+ patients (n = 2) (2 × IId) 0
[51] India Adults and children (n = 14) (6 × IIc; 5 × IId; 3 × IIe) 43
[52] India Children (n = 6) (1 × IIc; 1 × IId; 2 × IIm; 2 × IIn) 17
[21] India Children (n = 7) (7 × IIc) 100
[53] India HIV+ patients (n = 9) (5 × IIb; 3 × IIc; 2 × IIg) 33
[54] Iran Children (n = 15) (7 × IIa; 8 × IId) 0
[55] Iran Children (n = 17) (6 × IIa; 11 × IId) 0
[56] Iran Children (n = 22) (7 × IIa; 15 × IId) 0
[57] Japan Humans: not specified (n = 2) (1 × IIa; 1 × IIc) 50
[58] Japan Humans: not specified (n = 1) (1 × IIa) 0
[59] Jordan Adults and children (n = 2) (1 × IIa; 1 × IId) 0
[60] Jordan Children (n = 13) (3 × IIa; 2 × IIc; 8 × IId) 15
[61] Kuwait Children (n = 61) (29 × IIa; 12 × IIc; 20 × IId) 20
[9] Kuwait Children (n = 59) (27 × IIa; 2 × IIc; 29 × IId;1 × IIf) 3
[62] Lebanon Adults and children (n = 5) (5 × IIa) 0
[63] Malaysia HIV+ patients (n = 13) (12 × IIa; 1 × IId) 0
[64] Malaysia HIV+ patients (n = 1) (1 × IId) 0
[65] Yemen Adults and children (n = 7) (7 × IIa) 0
Africa
[66] Egypt Adults and children (n = 5) (5 × IId) 0
[67] Egypt Children (n = 14) (7 × IIa; 7 × IId) 0
[17] Equatorial Guinea HIV+ patients (n = 10) (7× IIc; 3 × IIe) 70
[68] Ethiopia HIV+ patients (n = 82) (71 × IIa; 1 × IIb; 2 × IIc; 5 × IId;
1 × IIe; 2 × If-like 2)
2
[69] Ethiopia Adults and children (n = 12) (12 × IIa) 0
[16] Ghana Children (n = 37) (30 × IIc; 7 × IIe) 81
[15] Kenya Children (n = 19) (19 × IIc) 100
[70] Madagascar Children (n = 1) (1 × IIc) 100
[71] Malawi Children (n = 2) (1 × IIc; 1 × IIe) 50
[72] Nigeria HIV+ patients (n = 1) (1 × IIc) 100
[73] Nigeria HIV+ patients (n = 1) (1 × IIc) 100
[74] Nigeria Adults and children (n = 1) (1 × IIe) 0
[75] Nigeria Children (n = 2) (2 × IIc) 100
[76] Nigeria HIV+ Adults (n = 8) (4 × IIc; 4 × unspecified) 50
[18] Nigeria Children (n = 23) (2 × IIa; 17 × IIc; 2 × IIi; 2 × IIm) 74
[77] Sao Tome and Principe Children (n = 5) (2 × IIa; 3 × IId) 0
[78] South Africa Children (n = 5) (1 × IIb; 3 × IIc; 1 × IIe) 60
[79] South Africa HIV + children (n = 5) (5 × IIc) 100
[80] Tunisia Children (n = 4) (2 × IIa; 2 × IId) 0
[22] Uganda Children (n = 15) (10 × IIc; 1 × IIg; 1 × IIh; 3 × IIi 3) 67
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Table 1 Cryptosporidium parvum subtype frequency distributions in published literature ranked by continent and country.
(Continued)
Reference Country Population Total number C. parvum isolates
subtyped and numbers of subtypes
Proportion C. parvum IIc
of C. parvum subtyped (%)
Europe
[81] Belgium Adults and children (n = 6) (4 × IIa; 1 × IIc; 1 × IId) 17
[82] Czech Republic Adults (n = 1) (1 × IIa) 0
[83] Denmark Adults and children (n = 34?) (15 × IIa; Others not stated) 0
[24] England & Wales, UK Adults and children (n = 66) (56 × IIa; 1 × IIc; 9 × IId) 2
[84] Estonia Human contact with calves (n = 1) (1 × IIa) 0
[85] France Adults (n = 1) (1 × IIa) 0
[86] Ireland Adults and children (n = 249) (249 × IIa) 0
[87] Ireland Adults and children (n = 79) (78 × IIa; 1 × IId) 0
[44] Italy AIDS patients (n = 8) (4 × IIa; 4 × IIc) 50
[88] Portugal HIV+ patients (n = 25) (9 × IIa; 1 × IIb; 7 × IIc; 8 × IId) 28
[89] Romania Children (n = 4) (4 × IId) 0
[90] Scotland Adults and children (n = 87) (82 × IIa; 2 × IIc; 2 × IId; 1 × IIg) 2
[91] Slovak Republic Humans: not specified (n = 1) (1 × IIa) 0
[92] Slovenia Humans: not specified (n = 31) (29 × IIa; 1 × IIc; 1 × IIl) 3
[93] Spain Adults and children (n = 12) (7 × IIa; 1 × IIc; 4 × IId) 8
[94] Spain Adults and Children (n = 7) (6 × IIa; 1 × IId) 0
[95] Spain Children (n = 3) (3 × IIa) 0
[96] Spain Adults and children (n = 163) (146 × IIa; 3 × IId; 14 × IIn) 0
[23] Sweden Adults and children (n = 108) (89 × IIa; 12 × IIc; 24 × IId; 1 × IIe; 2 × IIo) 11
[25] The Netherlands Humans: not specified (n = 13) (9 × IIa; 1 × IIc; 3 × IId) 8
[97] UK Humans: not specified (n = 16) (11 × IIa; 1 × IIc; 3 × IId; 1 × IIe) 6
North America
[98] Canada Humans: not specified (n = 7) (7 × IIa) 0
[99] Canada Adults and children (n = 5) (5 × IIa) 0
[100] Canada Humans: not specified (n = 4) (4 × IIa) 0
[19] Jamaica HIV+ patients (n = 7) (7 × IIc) 100
[101] Mexico Children (n = 2) (2 × IIa) 0
[102] USA Humans: not specified (n = 5) (5 × IIa) 0
[103] USA Humans: not specified (n = 30) (30 × IIa) 0
South America
[104] Brazil, Argentina Adults and Children (n = 3) (2 × IIa(mixed with hominis); 1 × IIc) 33
[12] Peru Children (n = 15) (15 × IIc) 100
[20] Peru HIV+ patients (n = 22) (22 × IIc) 100
Australia/Oceania
[28] Australia Humans (n = 14) (14 × IIa) 0
[27] Australia Adults and children (n = 21) (21 × IIa) 0
[29] Australia Farm workers (n = 7) (5 × IIa; 1 × IId; 1 × IIa/IId) 0
[30] Australia Adults and children (n = 80) (70 × IIa 79; 1 × IId) 0
[31] Australia Adults and children (n = 49) (48 × IIa; 1 × IId) 0
[26] Australia Humans: not specified (n = 32) (30 × IIa; 1 × IIc; 1 × IId) 3
[105] Australia Humans: not specified (n = 24) (23 × IIa; 1 × IIc) 4
[32] Australia Humans: not specified (n = 4) (4 × IIa) 0
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reported a proportion of 3%, or they did not find any C.
parvum IIc within their samples [27–33].
In order to further investigate the possible drivers of
the heterogeneity, we undertook regression analysis of
all studies reporting data from a single country where
we could allocate GDPpc, sanitation and water coverage
data. The results of the analyses are shown in Table 3. It
can be seen that in the single predictor analysis that
increasing GDP, improved access to sanitation and water
supply are all strongly associated with a reduced relative
proportion of C. parvum IIc. Also, those studies that are
focused primarily on people with HIV show a greater
relative proportion of C. parvum IIc. In the final model
both GDP and % access to improved water was dropped
from the model leaving % access to improved sanitation,
year of publication and whether the study focus was on
people living with HIV. The % access to improved sani-
tation and focus on HIV was particularly strong. The
relative proportion of C. parvum IIc declined by 3.3%
(95% CI: 2.8–4.4%) for every 1% increase in national
sanitation coverage. Similarly, the relative proportion of
C. parvum IIc was 3.4 (95% CI: 1.4–8.2) times greater in
studies focusing on people with HIV.
Additional file 2: Figure S1 indicates proportion of C.
parvum IIc found in studies ordered in increasing sani-
tation coverage of country of study. Figure 2 shows the
pooled relative prevalences for the three most common
subtypes by quartile of proportion of the population with
access to improved sanitation. Cryptosporidium parvum
IIc is seen in a higher proportion in countries with low
% sanitation coverage, and the proportion of C. parvum
IIc seen in countries with high % sanitation coverage is
much lower, or even none at all. This is in contrast to
the subtype IIa, which appears to be seen at a higher
proportion in countries with a higher % sanitation cover-
age, and subtype IId which shows a mixed picture but
appears to cluster in Arabic countries. We did not include
IIe in this analysis as the numbers were small - IIe was
found in small numbers in 11 studies, of which 6 were
in the lowest quartile for sanitation provision and one
from a mix of countries most of which would have been
in the lowest quartile. No IIe strains were reported
from countries in the highest quartile.
Discussion
This is the first systematic study, to our knowledge, in-
vestigating worldwide prevalence of C. parvum IIc and
correlating this with GDP and sanitation data. We have
illustrated a striking finding of high proportion of C.
parvum IIc in low- and middle-income countries and
extremely strong relationship between C. parvum IIc
proportion and GDP and inadequate access to improved
sanitation. This is especially pertinent when considering
the World Health Organisation Millennium Development
Goal of improved sanitation as many low-income countries
have made little or no progress towards this goal [34].
Table 1 Cryptosporidium parvum subtype frequency distributions in published literature ranked by continent and country.
(Continued)
Reference Country Population Total number C. parvum isolates
subtyped and numbers of subtypes
Proportion C. parvum IIc
of C. parvum subtyped (%)
[106] Australia Humans: not specified (n = 23) (18 × IIa; 5 × IIc) 22
[33] New Zealand Humans: not specified (n = 41) (41 × IIa) 0
Multiple continents
[47] Sub-Saharan Africa and
Southeast Asia
Children (n = 37) (21 × IIc; 13 × IIe; 3 × IId) 57
[107] Iran, Malawi, Nigeria, UK,
Vietnam
Children (n = 9) (4 × IIa; 2 × IIc; 3 × IId) 22
[108] Australia + Europe Adults and children (n = 11) (9 × IIa; 1 × IIc; 1 × IId) 9
[109] China, Guatemala, India,
Kenya, Portugal, Slovenia
Humans: not specified (n = 13) (4 × IIa; 5 × IIb; 4 × IIc) 31
Table 2 Pooled proportion of GP60 subtypes of C. parvum
Subtype No. of studiesa
(n = 85)
Pooled proportion 95% CI
IIa 58 0.53 0.43–0.63
IIb 5 0.0097 0.0058–0.015
IIc 43 0.19 0.13–0.26
IId 36 0.12 0.082–0.16
IIe 11 0.027 0.016–0.039
IIf 2 0.0087 0.0050–0.013
IIg 3 0.0083 0.0048–0.013
IIh 1 0.0075 0.0042–0.012
IIi 3 0.0087 0.0050–0.013
IIm 3 0.0085 0.0049–0.013
IIn 2 0.012 0.0075–0.017
IIo 1 0.0083 0.0048–0.013
aNumber of studies with at least one of the subtypes
Abbreviation: CI confidence interval
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The subtype C. parvum IIc is interesting as it is different
to other C. parvum in that it is considered anthroponotic
whereas other subtypes of C. parvum are zoonotic and
tend to infect a wide range of animals in addition to
humans. Cryptosporidium parvum IIc has never been
found in livestock or pet animals, although there are three
reports of a particular IIc subtype (IIcA5G3J) being found
in hedgehogs [35–37]. However, these may not reflect true
infection, rather ingestion from an environment faecally
contaminated with C. parvum IIc from human waste.
In contrast, C. hominis, the species of Cryptosporidium
defined by its predominantly anthroponotic transmission
characteristics, has been reported in livestock [7] and also
recently in domestic dogs in Spain [38]. This review
Table 3 Negative binomial meta-regression analyses of proportion of C parvum that were IIc across 80 analysable studies (studies
reporting data from a single country where GDPpc, sanitation and water coverage data could be allocated)
Predictor Single predictor analyses Final model
Proportion ratio 95% CI P-value Proportion ratio 95% CI P-value
Log10 GDP per capita US$2005 0.303 0.167–0.549 0.0001
% population with access to improved sanitation 0.969 0.955–0.983 <0.0001 0.967 0.956–0.972 <0.0001
% population with access to improved drinking water 0.943 0.914–0.975 0.0002
Year of publication 0.907 0.815–1.022 0.108 0.888 0.794–0.994 0.039
Study focus on HIV-positive individuals 3.263 1.096–9.717 0.034 3.414 1.428–8.162 0.006
Abbreviation: CI confidence interval
Fig. 2 Pooled relative prevalence of three most common C. parvum subtypes grouped by quartile of proportion of population with access to
improved sanitation with Q1 representing the quartile with least access to improved sanitation
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clearly demonstrates that it is anthroponotic C. parvum
that is causing the majority of disease in low- and middle-
income countries, rather than zoonotic C. parvum. This is
in spite of the often close proximity people may have with
animals in low-income settings, and is thus more likely
related to the widespread faecal contamination of both
food and water sources in these settings. This finding will
have implications for public health and should influence
measures to prevent infection and risks of ongoing
transmission.
The strong association between C. parvum IIc and inad-
equate access to improved sanitation is worthy of comment.
Given the prior association between outbreaks of crypto-
sporidiosis and waterborne disease [39], one would have
expected the association to be strongest with inadequate
access to drinking water. The fact that this is not the case
needs to be explained. It is accepted that C. hominis is more
common in low-income countries and that C. hominis is a
human pathogen [40] (although it has rarely been reported
in livestock [7] and in dogs [38]). Epidemiological studies
that have found inadequate household sanitation is a risk
factor for cryptosporidiosis infection in low-income coun-
tries including India [41], Venezuela [42] and Peru [43].
Therefore, the higher prevalence of C. hominis compared to
C. parvum in low income countries observed suggests that
anthroponotic transmission rather than zoonotic transmis-
sion is the main pathway in such countries, and this may
explain the higher relative proportion of C. parvum IIc in
those same countries. However, there may be other reasons
for seeing a higher relative proportion of C. parvum IIc,
including increased virulence or prolonged shedding for
example. Our study focused on C. parvum subtypes, and
thus C. hominis subtypes were not included. It is possible
that certain C. hominis subtypes would also show increased
prevalence in lower income countries, particularly for
example IbA10G2 which is thought to be more virulent
[12], but this would need to be systematically studied in
order to make any conclusions.
Data within this systematic review were not robust
enough to draw conclusions about the virulence of C.
parvum IIc. However, it is possible that C. parvum IIc is
more virulent than other C. parvum subtypes, as we know
now C. parvum IIc is causing the majority of C. parvum
infections in low-income settings where morbidity and
mortality due to Cryptosporidium infections is highest.
However, our data cannot provide the evidence for this,
and it is plausible that there are host susceptibility factors
involved which make C. parvum IIc more prevalent, but
not necessarily more virulent, as there may be other
subtypes that may cause less cases, but potentially more
virulent disease. In addition, as C. parvum IIc is anthropo-
notic it may act more like C. hominis than zoonotic C.
parvum and research has previously suggested that C.
hominis is more virulent than C. parvum [11]. One
observational study [44] stratified AIDS patients with
cryptosporidiosis into three groups (mild, moderate and
severe) based on symptom features, and in the severe
group the only subtype of Cryptosporidium found was C.
parvum IIc. In addition, they suggested that wasting syn-
drome was strongly linked to the subtype IIc, with wasting
seen in four out of four patients with IIc subtype, whereas
no wasting syndrome was seen in patients with Ia (1 patient)
and IIa (4 patients) subtypes of Cryptosporidium. The study
was, however, limited by its small size as it included only
nine cases of cryptosporidiosis, and the patient population
included AIDS patients only. It does though, raise the ques-
tion of whether C. parvum IIc causes more severe disease
demonstrating the need for further research to address
this. Well conducted, adequately powered epidemio-
logical studies investigating differences in clinical symp-
toms, illness duration and long-term sequelae between
different subtypes would be able to provide data to answer
this question.
There are several limitations of this review. The first is
that it relied on published studies to report the proportion
of C. parvum IIc, and these studies are not systematic
studies of subtyping. Instead subtyping tends to be done
on a subset of samples, often due to expense, which can
mean small numbers of subtyped samples are available for
analysis. In addition, earlier studies often did not subtype,
before gp60 subtyping became more widespread, and thus
these studies could not be included in this review. Gp60
subtyping is the commonly used method for subtyping
Cryptosporidium, but concerns have been raised as to
whether it could be missing some genetic diversity and
the role of multi-locus typing has been investigated [45].
However, a consensus is yet to be reached and as such
gp60 subtyping has remained the mainstay of Cryptospor-
idium subtyping, although recently a working group has
been set-up to implement and establish a multi-locus
genotyping scheme for Cryptosporidium [46]. Regarding
the statistical analysis relating to GDP and percentage
access to improved sanitation and improved water supply,
multiple variate parameters were not undertaken due to
high degrees of co-lineality.
With an increased emphasis on Cryptosporidium as a
pathogen capable of causing severe disease and now
recognised to be the second leading cause of death from
diarrhoeal disease in children under the age of five [5],
this study emphasises how anthroponotic C. parvum IIc
is disproportionately affecting low income countries and
demonstrates a clear link with sanitation.
There is an estimated disease burden of 7.6 million
diarrhoeal cases due to Cryptosporidium annually [47]
and recent understanding has highlighted the import-
ance of anthroponotic Cryptosporidium in causing these
infections in sub-Saharan Africa and South Asia, with C.
hominis responsible for 77.8% and C. parvum 9.9% of
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these Cryptospordium infections. Of the C. parvum cases,
91.9% were anthroponotic, of which the far majority were
IIc (57%) and then IIe (35%) [47]. Extrapolating this infor-
mation suggests a C. parvum disease burden of three
quarters of a million cases, with more than half of these
caused by IIc, resulting in significant morbidity and mor-
tality from the parasites comprising this GP60 subtype.
This corresponds to our study finding of high proportion
of C. parvum IIc in low-income countries, where the
biggest burden of diarrhoeal disease in children is seen,
and clearly any intervention to reduce this is desirable.
Given the disease burden associated with cryptosporidiosis
in low-income countries and the current lack of an effective
treatment or vaccine, there is a need for improved preven-
tion. Our findings and those of the few other studies
that have investigated suggest that improving sanitation
provision may be the most important intervention to
reduce the burden of disease from cryptosporidiosis
and its associated increased risk of death in young chil-
dren. We would support the importance of achieving the
Sustainable Development Goal on sanitation provision.
Conclusions
Our systematic study has shown that anthroponotic C.
parvum IIc predominates in lower-income countries with
poor sanitation and in HIV positive individuals, in con-
trast to higher-income countries where it is rarely evident.
Considering the large disease burden of cryptosporidiosis
in low-income countries and the post-infectious virulence
of other anthroponotic Cryptosporidium species such as
C. hominis, C. parvum IIc plays an increasingly apparent
role in this disease process. Given the current lack of
effective treatment or vaccine, interventions to improve
sanitation provision may be the best option to try and
reduce the cryptosporidiosis disease burden and associ-
ated childhood deaths in lower income countries.
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